Theraclion SA (TCLIF) Stock Price & Analysis
Theraclion SA (TCLIF) — price $0.532 (0.00%), as of the Nov 19, 2026 trading session; market cap $39.3M.
Educational signal · not a buy or sell recommendation · How to read this
Theraclion SA · TCLIF
Theraclion S.A. is a French medical device company specializing in non-invasive echotherapy solutions. Their products, SONOVEIN and ECHOPULSE, target varicose veins, thyroid nodules, and breast fibroadenomas.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.532 | |
| Change on the day | 0.00% | |
| Market capitalisation | $39.3M | |
| Shares traded on the day | 100 |
Price & events
What is Theraclion (TCLIF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Theraclion SA (TCLIF) is the company analyzed here. It employs 40 people. In Q2 FY2026 it reported revenue of €657,849 and net income of -€4M. The market values it at $39.3M.
What do the latest results show for Theraclion (TCLIF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €657,849.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €657,849 | -€4M | -€0.05 (diluted) |
| Q4 FY2025 | €351,867 | -€3M | -€0.05 (diluted) |
| Q2 FY2025 | €944,000 | -€3M | -€0.06 (diluted) |
| Q4 FY2024 | €1M | -€3M | -€0.07 (diluted) |
What are the financial strengths and risks for Theraclion (TCLIF)?
Short answer · as of
The distress and quality screens read Altman Z -0.48 · Piotroski F 2. Trailing ratios: ROE 453.1% · ROA -45.7% · current ratio 2.67 · earnings yield -14.4%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -0.48 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TCLIF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TCLIF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: TCLIF Stock
These answers are editorial: 1 of these 8 answers is drawn from the TCLIF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is TCLIF a good stock to buy?
Stock Expert AI does not rate TCLIF buy, sell or hold. Theraclion SA has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TCLIF stock price today?
The last price recorded for Theraclion SA (TCLIF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Theraclion S.A. do?
Theraclion S.A. is a medical device company that develops and markets echotherapy solutions using high-intensity focused ultrasound (HIFU). Their primary products are SONOVEIN, a robotic system for the non-invasive treatment of varicose veins, and ECHOPULSE, a robotic system for the non-invasive treatment of thyroid nodules and breast fibroadenomas.
What are the key factors to evaluate for TCLIF?
Evaluate TCLIF on fundamentals, analyst consensus, and risk factors. Theraclion's SONOVEIN system offers a potential solution for patients seeking a pain-free and scar-free treatment option. Not financial advice.
How frequently does TCLIF data refresh on this page?
TCLIF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TCLIF's recent stock price performance?
Theraclion SA (TCLIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary echotherapy technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TCLIF overvalued or undervalued right now?
Theraclion SA (TCLIF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TCLIF before investing?
Before investing in Theraclion SA (TCLIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 9 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com